1. A method of treating an autoimmune disease in a mammalian patient, preferably a person in need of such treatment, comprising administering to the patient a compound that is a modulator or agonist of the S1P receptor, or a pharmaceutically acceptable salt or prodrug thereof, in accordance with a dosage regimen that is established taking into account the content of lymphocytes in the patient's blood. 2. The method of claim 1, wherein the autoimmune disease is multiple sclerosis. The method of claim 1, wherein the daily dose of an S1P receptor modulator or agonist is increased if the patient’s blood lymphocyte content is higher than the target blood lymphocyte level and reduced if the patient’s blood lymphocyte content is lower than the target blood lymphocyte level. . The method according to claim 3, where the daily dose, established taking into account the content of lymphocytes in the patient’s blood, is adjusted as necessary so that it is approximately not less than 0.5 mg and not more than 5.0 mg. The method according to claim 4, wherein the daily dose set taking into account the content of lymphocytes in the patient’s blood is adjusted as necessary so that it is approximately not less than 0.2 mg and not more than 5.0 mg. The method according to claim 4, where the daily dose is established taking into account the content of lymphocytes in the patient’s blood, adjust as necessary so that it is approximately not less than 0.25 mg and not more than 5.0 mg. The method of claim 3, comprising: (a) administering a S1P receptor modulator or agonist, or a pharmaceutically acceptable salt or prodrug thereof, to a patient in an initial dose of about 1.0 to 2.0 mg / day during the initial period； (b) a comparison of the lymphocyte content in the blood of a patient established in1. Способ лечения аутоиммунного заболевания у пациента-млекопитающего, предпочтительно человека, нуждающегося в таком лечении, включающий введение пациенту соединения, которое является модулятором
